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Solid organ transplantation has transformed the lives of many children and adults by providing treatment for
patients with organ failure who would have otherwise succumbed to their disease. The first successful transplant
in 1954 was a kidney transplant between identical twins, which circumvented the problem of rejection fromMHC
incompatibility. Further progress in solid organ transplantation was enabled by the discovery of immunosup-
pressive agents such as corticosteroids and azathioprine in the 1950s and ciclosporin in 1970. Today, solid organ
transplantation is a conventional treatment with improved patient and allograft survival rates. However, the
challenge that lies ahead is to extend allograft survival time while simultaneously reducing the side effects of
immunosuppression. This is particularly important for children who have irreversible organ failure and may
require multiple transplants. Pediatric transplant teams also need to improve patient quality of life at a time of
physical, emotional and psychosocial development. This review will elaborate on the long-term outcomes of
children after kidney, liver, heart, lung and intestinal transplantation. As mortality rates after transplantation
have declined, there has emerged an increased focus on reducing longer-term morbidity with improved
outcomes in optimizing cardiovascular risk, renal impairment, growth and quality of life. Data were obtained
from a review of the literature and particularly from national registries and databases such as the North American
Pediatric Renal Trials and Collaborative Studies for the kidney, SPLIT for liver, International Society for Heart and
Lung Transplantation and UNOS for intestinal transplantation.
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& INTRODUCTION
Patient survival after transplantation has improved
substantially over the last decades. For example, 5-year
survival for deceased donor renal transplantation increased
from 91% in the 1987-1995 era to 96% in the 1996-2007 era
(1). The published data on patient and allograft survival
rates for children after kidney, liver, heart, lung and
intestinal transplantation are summarized in Table 1.
Improvements have mainly occurred in the peri-operative
period and have been attributed to better surgical and
micro-anastomosis techniques, improved donor procure-
ment and matching schemes and advanced HLA testing
methods. HLA typing is now more precisely performed by
direct DNA sequencing, and HLA antibodies are detected
through flow cytometric bead-based technology (2). Flow
cytometry has the advantage of being highly sensitive and
enables the prediction of alloimmune responses before
transplantation, which can be utilized in virtual cross-
matching. This technology also enables the detection of
alloantibodies synthesized de novo after transplantation.
However, there are concerns that modern bead-based
techniques may be too sensitive and identify non-clinically
relevant antibodies because of differences in the conforma-
tion of the antigen between the beads in vitro and the actual
in vivo protein structure (2). Regardless, the incidence of
hyper-acute rejection resulting from pre-formed antibodies
is now very low.
Transplantation in infants requires special consideration
because of the mismatch in donor and recipient size and
because the indications, such as congenital abnormalities of
the kidney and urinary tract for renal transplantation,
biliary atresia for liver transplantation and congenital heart
disease for cardiac transplantation, are specific to children.
Transplantation in infants is also associated with decreased
patient and allograft survival rates. In renal transplantation,
the overall patient survival rate is 93% at 3 years compared
with 96–99% for older children receiving deceased donor
transplants, although the difference is not as large for liv-
ing donor transplants (1). However, if they survive the
immediate post-operative period, infants exhibit compar-
able outcomes to older children.
A recent development that has increased organ avail-
ability is transplantation across the ABO blood group
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barrier. The Paediatric Heart Transplant Study database of
931 ABO-incompatible cardiac transplants performed in
recipients less than 15 months old reported reduced
rejection and no differences in mortality (3). In a small
single-center study of liver transplantation for infants under
5 kg, survival was comparable to ABO-compatible trans-
plants (4). Infancy is considered to be an immune-privileged
time for transplantation because infants have a less-
developed immune system and higher acceptance of ABO
mismatches. In older children, antibody removal using, for
example, plasma exchange and rituximab, can be utilized to
decrease blood group antibody levels to acceptable levels
(aiming for a dilution ratio of 1:8) (5). In a series of 52
consecutive kidney transplants, Shishido et al. reported no
differences in glomerular filtration rates (GFRs) or patient
and allograft survival rates compared with ABO-compatible
transplants (6). The levels of blood group antibody titers
remained low after transplantation, which suggests a degree
of accommodation towards blood group glycoproteins. In
ABO-incompatible liver transplantation, a recent meta-
analysis also revealed similar patient and allograft outcomes
compared with ABO-compatible patients (7).
It is particularly difficult to perform transplantation in
sensitized patients with positive cross-matches who exhibit
positive preformed HLA antibodies. This is often expressed
as the percentage of panel-reactive antibodies (PRA), which
is tested against a set HLA panel, or the calculated reaction
frequency (cRF), which uses the value for the specific HLA
antibody calculated against the known population fre-
quency (8). A high PRA or cRF value limits the availability
of donors because patients with persistently positive HLA
are excluded from the donor pool. These patients also
exhibit lower allograft and patient survival rates and higher
rates of allograft rejection after transplantation (9,10).
Antibody-depleting strategies using plasma exchange,
double filtration plasmapheresis, intravenous immunoglo-
bulin (IVIg), rituximab and, more recently, the plasma cell-
depleting agent bortezomib have produced variable results
in children (8,11). However, this sensitized group is
growing because of the increase in patients requiring re-
transplantation who are sensitized to their failed allografts.
Mortality is highest immediately after transplantation,
particularly in to technically difficult patients (12,13). If
patients survive beyond this period, late mortality is low
and is more often associated with the side effects of
immunosuppression. In fact, conditional survival for infant
heart transplants who survived the first transplant year
approaches 20 years [19.2 years for those transplanted
between the ages of 1-10 years and 15.9 years for older
children (13)]. The causes of mortality therefore evolve after
transplantation, with the major late causes of mortality
including sepsis, cardiovascular causes and post-transplant
lymphoproliferative disorder (PTLD) (14). Chronic allograft
dysfunction leading to loss of the allograft is also an
important cause of mortality and will be discussed subse-
quently. Infections have overtaken rates of rejection as the
major cause of hospital admission (13).
The rate of PTLD is highest in the first few years after
transplantation, which is related to higher doses of
immunosuppression, although the risks still persist longer
than a few years. The risk of developing PTLD is ,5% after
renal, liver and heart transplantation (15,16) and ,10% after
lung and intestinal transplantation. Pediatric patients are at
a higher risk of developing PTLD because more of them are
EBV-naı¨ve. Therefore, routine monitoring for EBV viremia
in these patients allows immunosuppression to be adjusted
but does not predict which patients will develop PTLD (17).
SOT recipients are also at risk for other types of cancers,
particularly skin cancer, genitourinary cancer, Kaposi
sarcoma and papillary thyroid cancer.
Allograft survival
Although allograft survival in the immediate post-
operative period has improved substantially, there have
been no significant improvements in longer-term allograft
survival. Figure 1 presents the renal allograft survival rates
after living donor transplantation by era in North America,
which are also representative of the rates for other
transplant recipients worldwide (1). There is no longer a
sharp decline in allograft survival early after transplanta-
tion, but the slope of allograft survival has not changed
between transplant eras. The change in early survival can
partly be explained by better control of early acute allograft
rejection. Acute renal allograft rejection in the first year after
transplantation has decreased from 54% pre-1990 to 8.6% in
2010 (1). Acute cardiac allograft rejection in the first year
after transplantation has decreased from 60% to 40% in the
last decade (18).
In the long term, chronic allograft dysfunction is caused
by both immune and non-immune causes. Infections play
an important role in patient morbidity and also lead to graft
decline. Children with congenital abnormalities of the
kidney and urinary tract with bladder dysfunction are
prone to repeated urinary tract infections, and this is
exacerbated by immunosuppression after transplantation.
The polyomavirus, BK virus, is renotrophic and can cause
tubulo-interstitial nephritis. In lung transplant recipients,
early phase respiratory viral infections are linked to
worsened allograft outcomes, and CMV has been implicated
in bronchiolitis obliterans.
Chronic antibody-mediated rejection (AMR) has been
postulated to be one of the main reasons for the slow
Table 1 - Patient and allograft survival of children after kidney, liver, heart, lung and intestinal transplantation. Living
Donor, Deceased Donor.
Organ Patient survival (%) Allograft survival (%)
1 year 5 year 10 year 1 year 5 year 10 year
Kidney, LD (top), DD (bottom) (1) 98.4 96.1 92.4 96.5 84.3-87 54
97.4 93.3 86.6 95.1 66-78.0 51
Liver (15) 84-89.8 82-84.8 77 84-93 81-88 75
Heart (13) 80 68 58 86-90 68-75
Lung (12) 83 54 44 (7 yr) 78-88 35-41
Intestinal (34) 80-95 77 46 88 74 58
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invariable progression to allograft loss (19,20). Chronic AMR
has been associated with the de novo development of post-
transplant donor-specific antibodies (DSA) (21). These
antibodies are produced by B-cells that have developed
high-affinity receptors targeting HLA mismatches arising
from the graft and have undergone class switching from IgM
to IgG with subsequent maturation to plasma cells and
memory B-cells (22,23). Memory B-cells and memory T-cells
are difficult to address using current immunosuppressive
therapy. One option is to use rituximab, a B-cell depleting
agent, and IVIg, which promotes antibody immunomodula-
tion, to treat active disease and to increase baseline
suppression with the addition of mycophenolate mofetil
(MMF), which has B-cell anti-proliferative effects (24). The
reasons why some patients develop DSA are not known, but
one clear factor is non-compliance with immunosuppressive
medications. In addition, DSA levels can fluctuate in
pediatric patients and do not always lead to chronic allograft
dysfunction (25). This is an area under intense investigation,
and future techniques may involve immunoglobulin profil-
ing and complement-fixing HLA antibodies (26,27).
AMR is characterized by microvascular injury on allograft
biopsy staining and is associated with complement activa-
tion detected by C4d staining. In the IHSLT registry, AMR
of pathological Grade 2 or higher was present in 18% of
protocol endomyocardial biopsies, representing 59% of
patients (28). Patients with Grade 3 AMR had more cardiac
allograft vasculopathy and increased cardiovascular mor-
tality. The role of AMR in liver transplantation is currently
under investigation. C4d staining is present not only in
AMR but also in recurrent liver disease and hepatic necrosis
(29). However, C4d staining in the presence of DSA often
co-exists with cellular rejection and can be steroid-resistant
(30).
Current immunosuppression strategies usually consist of
a calcineurin inhibitor (CNI) and an anti-proliferative agent
in addition to corticosteroids, with variable use of mono-
clonal antibodies at induction (1,12,13). Current immuno-
suppression strategies aim to balance the prevention of
rejection and the side effect profile. Tacrolimus has
generally replaced ciclosporin as the first-line CNI because
of its better potency and reduced nephrotoxicity (1,12,13,31).
Basiliximab and daclizumab are IL2R-alpha monoclonal
antibody inhibitors that are effective T-cell activation
blockers, but they have not been demonstrated to improve
renal allograft outcomes in pediatric renal transplant
recipients when used in addition to the standard triple
therapy of prednisolone, azathioprine and tacrolimus (32).
However, the use of IL2R-alpha monoclonal antibody
inhibitors allows rapid weaning of other immunosuppres-
sive agents, such as corticosteroids (33). The use of
induction agents has also increased in heart and lung
transplantation but has not been associated with improve-
ments in graft outcomes at 5 years post-transplant (12,13). In
intestinal transplantation, the use of IL2-blockers has been
effective at reducing acute rejection rates but can be
associated with an increased risk of PTLD long after
transplantation (34).
Tolerance is defined as stable allograft function in the
absence of any immunosuppression. Tolerance can be
induced via bone marrow transplantation, as has been
described in a case series of multiple myeloma patients who
subsequently received renal transplants from the same
donor (35). However, caution is warranted, as bone marrow
transplantation carries a high risk of mortality currently
exceeding that of standard solid organ transplants and
therefore remains an experimental procedure. Recently, a
modified reduced induction regimen with infusion of a
facilitating cell population has been described with positive
results. Persistent graft chimerism and stable allograft
function appear to be present at one-year follow-up, but
longer-term results are pending (36).
Figure 1 - Renal allograft survival after living donor transplantation by era. Taken from the NAPRTCS 2011 Annual Report (1).
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Tolerance has also been reported in patients who have
been weaned from immunosuppression either through non-
compliance or secondary to medical reasons. However,
these cases remain rare, particularly in the pediatric
literature. Spontaneous tolerance has best been described
in liver transplantation, and currently active trials are
aiming at active immunosuppression weaning with close
follow-up (37,38). Studies of liver transplant tolerance have
reported an increase in NK and NKT cells (39). In adult
renal transplant tolerant patients, two cross-validated
microarray studies have reported an increase in B cell
frequency with a concomitant increase in B cell gene
transcript signature (40,41). Studies are currently under
way to prospectively validate these gene markers for
tolerance.
Tolerance can also be viewed as a continuum rather than
a separate state. There have been concerns that tolerance
may not be meta-stable and that infections could tip the
balance towards rejection. Therefore, a compromise may
involve accepting minimal immunosuppression (such as
utilizing a single immunosuppressive agent) rather than a
complete cessation of all immunosuppression. The chal-
lenge is to identify biomarkers of tolerance to enable safe
weaning of immunosuppression.
Cardiovascular risk factors
Cardiovascular-related deaths are a major component of
mortality. Transplant recipients often exhibit increased
cardiac dysfunction and usually present unexpectedly in
extremis. The main causes of cardiac death include heart
failure and arrhythmias (42), in contrast with the general
population, in which the major cause is progressive
ischemic heart disease. There are also differences in cardiac
lesions, as transplant recipients tend to exhibit global
arteriosclerotic calcification in the intima and media, in
contrast to the atherosclerotic lipid plaques found in elderly
patients. However, transplantation itself can improve
cardiac outcomes (14). For example, renal transplant
recipients exhibit improvements in cardiac hypertrophy
and reductions in diastolic dysfunction after transplanta-
tion, although not in all cases and often not back to the
normal condition (43-45).
Cardiovascular risk factors after transplantation are
interlinked and are increased as side effects of immuno-
suppression. Hypertension is common, as it is described in
50-75% of renal transplant recipients, and is associated with
left ventricular hypertrophy (46,47). The prevalence of
hypertension in liver transplant patients is reported to be
15-30% (48,49). Transplant recipients require 24-hour ambu-
latory blood pressure monitoring to unmask nocturnal
hypertension (46,49,50). Hypertension is a side effect of
corticosteroids and CNI, which also increases the risk of
metabolic syndrome [obesity, dyslipidemia and diabetes
mellitus (51,52)]. Corticosteroids increase the risk of devel-
oping new-onset diabetes after transplantation (NODAT) by
increasing peripheral insulin resistance, and CNI has a
direct toxic effect on insulin-producing beta-islet cells in the
pancreas. Registry studies have reported a prevalence of
CNI of 1.8-2%, 3% and 3-7% in cardiac, liver and renal
transplant recipients, respectively, and CNI is closely
associated with the level and type of immunosuppression
(53-55). In particular, although it provides a lower rejection
rate, tacrolimus also results in an increased risk of NODAT
compared with ciclosporin (31,56). In one study, tacrolimus
had an odds ratio of 9.1 for development of NODAT
compared with ciclosporin (57). In renal transplantation,
two different strategies have been investigated, namely
corticosteroid withdrawal and CNI minimization, which
are discussed below. Obesity is an increasing healthcare
problem that has clear cardiovascular consequences. The
prevalence of obesity has also risen in pediatric renal
transplant recipients from 8% before 1985 to 12.5% after
1985, with a more recent study estimating the prevalence
of diabetes to be as high as 30% (58,59). Obesity is
associated with a higher risk of death from cardiopulmon-
ary causes (adjusted relative risks of 3.65 for living donors
and 2.94 for deceased donors) and higher rates of allograft
loss (19% vs. 10%) in transplanted children. In liver
transplantation, the risk is 14-16% and remains high long
after transplantation (15,60). Obesity following cardiac
transplantation occurs less frequently and is estimated at
8%, possibly because of the focus of corticosteroid with-
drawal and the use of statins (61). The use of statins in
other solid organ transplant recipients requires further
investigation (62).
Renal dysfunction
Renal dysfunction is an important cause of morbidity
after transplantation. In severe cases, renal dysfunction
can lead to end-stage kidney disease requiring dialysis
and/or transplantation, but even in mild to moderate
cases, renal dysfunction can cause bone mineral disease,
vascular calcification and cardiomyopathy. The prevailing
risk factors common to solid organ transplant recipients
include renal dysfunction at the time of transplantation
and the use of CNI. Renal decline is often an insidious
process and requires long-term routine monitoring.
Follow-up studies of renal function after transplantation
are not comparable because of differences in GFR estima-
tions or measurements and different definitions of CKD.
One future option for standardization is to use the
definitions set by KDIGO.
The prevalence of renal dysfunction in liver recipients
was found to be 17.6% (GFR ,90 mL/min/1.73 m2) at a
mean of 5.2 years post-transplantation based on SPLIT data
(63). However, the prevalence of CKD was higher in two
other studies (25% and 32%) examining longer-term data
closer to ten years after transplantation despite their use of a
lower GFR cut-off (60 and 70 mL/min/1.73 m2, respectively
(63,64). In cardiac transplant patients, the rate of freedom
from late renal dysfunction (GFR ,60 mL/min/1.73 m2)
was 71% and 57% at five and ten years (65). The prevalence
of more severe renal dysfunction, defined as the require-
ment for dialysis and transplantation or as a plasma
creatinine level above 221 mmol/L, was 11% at 10 years
post-transplantation (66). In lung transplant recipients, renal
dysfunction was estimated to be 10% at 1 year, 23% at 5
years and 35% at 7 years post-transplantation (67); 21% of
intestinal transplant patients were found to exhibit stage
IV or V chronic kidney disease with GFR ,29 mL/min/
1.73 m2 after five years (68).
An important cause of nephrotoxicity is CNI usage with
ciclosporin and tacrolimus, which can cause glomerular
vascular constriction and shrinkage and in the long term
can result in interstitial fibrosis and arterial hyalinosis.
However, patients exhibit variability in the nephrotoxic
effects of CNI because of genetic polymorphisms in the
enzymes involved in CNI metabolism, particularly MDR1
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and CYP3A, and may suffer renal damage despite being
within the target drug range (69). Of the two CNIs,
tacrolimus is associated with less nephrotoxicity. Ta-
crolimus is associated with better GFRs and lower
rejection rates than ciclosporin in pediatric renal trans-
plant recipients (31). In patients with CNI toxicity, one
option is CNI minimization or even withdrawal with
intensification or substitution of alternative immunosup-
pressive agents, such as MMF or sirolimus. The timing of
CNI withdrawal is important, as nephrotoxicity from CNI
is not reversible when performed too late, but the chances
of successful withdrawal are improved if undertaken
later after transplantation (70,71). Although CNI mini-
mization has been shown to be effective in stabilizing
renal function decline, it must be monitored with caution,
as there has been evidence of increased rejection rates
(72-75). In addition, longer-term follow-up studies are
needed to ensure that the improvements are maintained,
particularly without an increase in AMR. For patients on
MMF, drug monitoring is important to ensure adequately
high therapeutic dosages, which may explain the increase
in rejection in other studies (76,77). Among patients on
the mTOR inhibitors sirolimus and everolimus who
exhibit improved renal function, there is a high incidence
of side effects, including aphthous ulcers, dyslipidemia,
myeloid suppression and proteinuria, necessitating the
conversion to alternative medications (78) and counter-
foing the benefit of CNI minimization (73,74,79). A new
immunosuppressive agent that was recently approved by
the FDA is the co-stimulatory inhibitor belatacept. In the
phase 3 trial BENEFIT, adult transplant recipients
prescribed belatacept with CNI avoidance exhibited
better GFRs at 3 years post-transplantation (80).
However, patients who are EBV-naı¨ve are contra-indi-
cated for this treatment because of the higher rate of
PTLD, which would exclude a large number of pediatric
patients from treatment with belatacept.
Growth
Because of their underlying chronic conditions, children
with organ failure are usually shorter than their peers prior
to transplantation but exhibit improved growth after
transplantation. Growth is important, as it is linked to
better functional outcomes in employment, education and
marital life (81,82).
NAPRTCS data have demonstrated that catch-up growth
is best achieved in children transplanted younger, especially
those below six years of age (Figure 2) (1). In children who
had achieved final adult height, the mean Z-score was
found to be -1.40; however, improvement was observed
over the years, with the most recent cohort exhibiting
Z-scores of -0.94 (1). Pediatric renal transplant recipients
treated with daclizumab, mycophenolate mofetil and a
quick corticosteroid wean over 4 days in the TWIST study
exhibited a mean SDS change of 0.16 compared with 0.03 in
the standard regimen group at 6 months with no increase
in rejection rates; longer-term data are being currently
analyzed (33). In a more recent study with 3-year outcomes,
growth was also better in the corticosteroid-free regimen in
a subgroup analysis of pediatric renal transplant recipients
under 5 years of age (change in SDS score: -0.43 vs. -1.07).
The corticosteroid-free regimen was safe, with similar
allograft survival, and the patients exhibited lower blood
pressure and cholesterol levels (83). These results have been
reproduced in other studies, which should prompt con-
sideration of early corticosteroid withdrawal if not complete
corticosteroid avoidance in uncomplicated transplants (84-
87).
The use of recombinant human growth hormone remains
controversial, especially as it may confer an increased risk of
PTLD. In the most recent Cochrane update, children who
were treated with growth hormone (28 IU/m2/week)
exhibited an increased height velocity of 3.88 cm/year
(88). In one non-randomized study, final height was
significantly higher in patients treated with growth hor-
mone, although the height in the control group was well
Figure 2 - Catch-up growth according to the age at renal transplantation. Taken from the NAPRTCS 2011 Annual Report (1).
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below the average (Z-score -1.88 vs. -3.48) (89). However, the
cost of this treatment is prohibitory in resource-poor
countries and has to be balanced against maximizing
nutrition and caloric intake, which can also produce very
good height outcomes (90). However, some studies did not
report the final adult attained height, and 25(OH) vitamin D
deficiency has also been associated with short stature (91). It
should be noted that puberty is not delayed in the majority
of pediatric transplant recipients, although they invariably
exhibit delayed bone age and achieve final height later (92).
Liver transplant recipients also exhibit catch-up growth
after transplantation. Similar to kidney transplantation
patients, children undergoing liver transplantation in
the current era exhibit better height outcomes (82). Im-
provements in SDS scores are largest immediately after
transplantation, partly because of the normalization of
digestive enzymes and food digestion. In the SPLIT registry,
the mean SDS score at 5 years after transplantation was -0.5
in the most recent cohort (82). Growth plateaus 3-5 years
after transplantation and, in a study examining 15-year
outcomes, height remained static at -0.47 SDS (93).
Improved height gain is associated with less corticosteroid
exposure and non-metabolic conditions (82). Corticosteroid-
free and corticosteroid withdrawal regimens have also been
used successfully (87,94).
Pediatric cardiac transplant recipients maintain their
height SDS score with little catch-up growth despite
improvements in weight (95). Lung transplant recipients
tend to be transplanted in their teens and exhibit growth
complications associated with their underlying disease,
which is typically cystic fibrosis. Growth after intestinal
transplantation is dependent on the re-establishment of
feeding and rejection episodes. Lacaille et al. managed to
achieve normal growth in two-thirds of their series of 31
children (96).
Quality of life
Although life-saving, solid organ transplantation is not
curative, and transplanted children continue to exhibit
chronic health problems throughout their life. Therefore,
transplantation should focus on extending the length of life
and also increasing the quality of life. The WHO defines
health as a state of complete physical, mental and social
well-being and not merely the absence of disease or
infirmity. This requires a holistic approach from the multi-
disciplinary transplantation team with involvement of
primary care physicians, psychologists, social workers and
the school, focusing on minimizing attention problems and
school absenteeism and maximizing long-lasting relation-
ships with peers and overall school performance.
Quality of life (QoL) can be measured by various indices,
which can be general or disease specific. General indices
allow comparisons to the general population and across
populations but do not address specific issues related to
transplantation. Transplant-specific indices are more sensi-
tive to changes in a child’s condition and are more useful for
measuring longitudinal changes. When possible, QoL
questionnaires should be answered by the children them-
selves. However, there is good agreement between the
results reported by children and those reported their
parents, although the agreement is higher for observable
behaviors than for non-observable emotional and social
functions (97).
Qualitative interview studies are also useful in identifying
concerns and highlight generic concerns such as physical
health limitations, emotions (including fears and worries
about future health, sadness arising from knowledge of their
parents worrying about them and self-blame for imposing
worry on family members) and school/social concerns
(such as poor attendance and bullying).
Pediatric renal transplant recipients exhibit good overall
outcomes after transplantation (98,99). A questionnaire
study of children transplanted before 1999 reported fair or
good outcomes in 95% despite a high prevalence of side
effects, and 50% of patients were married and reported
satisfaction in their married lives (81,100). The rate of
unemployment approached 27%, which was comparable
that in the general population, and a significant proportion
of the patients achieved a university qualification (81,98).
However, overall QoL scores were lower than those of
healthy peers (101-103). The worst outcomes of transplant
patients are related to the side effects of treatment
(including body image, obesity, short stature and ulcers)
and correlate to non-adherence, which in turn correlates to
allograft function (102). Patients also exhibit an increased
incidence of somatic complaints and anxiety and depression
(98,104). A study utilizing DSM IV criteria reported a 65%
risk of lifetime psychiatric disorders in transplant patients
compared with 60% in CKD patients and 37.5% in controls
(105).
Data from the SPLIT registry, including QoL data, are
available for multi-center studies. These data demonstrate
lower physical and psychosocial functioning compared with
matched peers but equivalent functioning to children with
other chronic conditions. PedsQL 4.0 Generic Core Scales
were all significantly lower in transplant patients (p,0.001),
with effect sizes ranging from 0.25 for self-reported
emotional functioning to 0.68 for self-reported school
functioning (with effect sizes greater than 0.5 considered
moderate and 0.8 considered large) (106,107). Patients
reported better scores than their parents. Time from
transplantation did not impact QoL, but length of stay,
number of subsequent days of hospitalization, lower height
z-scores, older age and a history of seizures exerted a
negative impact on QoL (106,107). In summary, transplant
patients exhibit lower QoL compared than the general
population but equivalent QoL to other chronic disease
patients.
Heart transplantation leads to dramatic improvements in
functional status and allows children to return to age-
appropriate activities, including physical recreational activ-
ities and school (108,109). One qualitative study found that
pediatric cardiac transplantation patients described their
lives as ‘mostly good’ or ‘fun’ and noted that they valued
the normal aspects of life (110). Another study reported that
the majority (78%) of patients exhibited improved psycho-
logical functioning after cardiac transplantation, which was
maintained after a decade. Good physical rehabilitation and
lifestyle were typically reported in 10% of patients trans-
planted in the early era who survived more than 20 years
(111). However, there is a subset of patients with identifiable
psychosocial problems, including anxiety, depression and
behavioral problems (108,112-114).
QoL studies for lung transplant recipients are limited
(115), although a reduced intensity of psychosocial pro-
blems has been suggested (116). In adult QoL studies,
general satisfaction with the transplantation decision and
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improved QoL scores compared with patients awaiting
transplant have been reported, but significant findings of
pain have also been reported (117,118). An important study
highlighted lower QoL scores in caregivers of lung
transplant recipients that were correlated with patient
survival rates (119), thus indicating an important avenue
of support to improve transplant outcomes.
In intestinal transplantation, one early study reported
similar QoL scores to population controls in self-reported
questionnaires but lower scores in parent assessments (120).
Therefore, despite the effects of disease on their health,
these children did not report that their daily functioning
was affected, which is an important point when counseling
families. This result was reproduced in two recent studies
(121,122).
Socioeconomic factors play an important role in the
psychosocial support network of children and their families.
Single-parent households, low level of caregiver education
and family conflicts are negative predictors of QoL
(106,107,123). A study evaluating family QoL scores found
that transplantation significantly disrupted daily activities
but did not affect family functioning as assessed by the
Family Assessment Device (107). The parents of transplant
children also suffer symptoms of post-traumatic stress
disorder, with a prevalence of nearly 40% determined using
DSM IV criteria in one study (124,125). Psychological effects
on siblings should also be considered in future research.
Physicians can minimize family disruption and potentially
improve compliance and outcomes by minimizing hospital
visits and facilitating follow-up assessments and blood tests
at local hospital networks.
The cognitive functioning of pediatric transplant recipi-
ents needs to be considered in conjunction with normal
brain development. However, cognitive function is deter-
mined by the underlying condition, as some diseases
present during infancy at the time of rapid neurodevelop-
ment and will therefore exhibit a larger impact on cognitive
function. Studies generally demonstrate a lower neurocog-
nitive score in transplant patients compared with the
general pediatric population. One study of pediatric renal
transplant recipients reported an FSIQ of 87 (normative
mean 100, SD 15) (126). Early renal transplantation has been
suggested to improve cognitive function in infants (127). In
liver transplantation patients, the FOG/SPLIT group high-
lighted a high prevalence of cognitive delays and learning
problems, with 26% of patients exhibiting ‘mild to moder-
ate’ IQ deficits and 4% exhibiting ‘serious delays’ (128).
However, these studies were performed in previous
transplant eras. More recent results may be more encoura-
ging, and longitudinal data are required to determine
whether there is any change or improvement in cognitive
function (125,129). Children with heart transplants are
affected by their period of cyanosis and any prolonged
episodes of brain ischemia resulting from circulatory arrest
and cardiopulmonary bypass. Heart transplantation there-
fore improves cognitive function, and developmental and
academic assessments have generally been in the normal
range (114,130).
Transition
Adolescence is a time when allograft recipients can rebel
with non-adherence to immunosuppression and may con-
sequently lose their functioning graft. Therefore, it is
important not only to provide additional support to young
adult allograft recipients but also to ensure that they have a
smooth transition to adult physicians, surgeons and multi-
disciplinary teams. The ideal transition process should be
individualized according to the needs of the patient and not
the requirements of the services. The patient transition
should involve adolescent-trained physicians, surgeons,
nurse specialists, pharmacists and allied health profes-
sionals, including the psychosocial team and other multi-
disciplinary team members, such as youth workers. Most
transplant centers provide a dedicated clinic within the
adult setting rather than a combined pediatric-adult clinic
and have no direct input or continuity from pediatric
services. However, the success of these clinics is dependent
on good communication between the two services, includ-
ing meetings between the pediatric and adult clinic staff to
plan coordinated care and the involvement of youth
workers and transition link staff, such as nurse specialists
(who can escort young people to the adult clinics if
required). However, a better model can be provided in
which both pediatric and adult professionals provide
ongoing care in a joint clinic from adolescence through to
adulthood, the duration of which can be individualized
(131). Transition programs are set up to improve patient-
related outcome measures and patient experiences.
However, improvement of patient outcomes can only be
achieved by careful preparation during the transitioning
process, with joint transition clinics identifying issues and
overcoming potential difficulties. Initially, young adults
should have their fears allayed through the allocation of a
key liaison member of the staff assisting in an informal visit
to the adult unit during the preparation for transfer. Young
adults may be reluctant to leave friends and healthcare
personnel, or they may lack maturity or have adherence
issues and an ongoing dependence on their parents or
guardians. The parents may be reluctant to leave familiar
staff and clinic surroundings and may resist attempts by the
adult service to enhance the self-advocacy of the child.
Financial or time barriers may also impede successful
transition from the healthcare system. Excellent commu-
nication channels are necessary between pediatric and adult
services, with the transfer of documentation (including
inpatient and outpatient medical and nursing notes, opera-
tion notes and longitudinal laboratory data, including
histopathology and radiology results and specialist reports).
Pediatric medical and nursing staff may exhibit emotional
attachment to patients and lack confidence in the potential
care given by health professionals in the adult clinic because
of differences in the attitudes and priorities of adult
services. Adult medical and nursing staff may lack
confidence in managing adolescents because of inadequate
training in child and adolescent development or the impact
of chronic disease. The staff may be concerned regarding
different dynamics of consultation (such as the presence of
parents in consultations). They may also lack confidence in
the pediatric staff if aware of differences in the attitudes and
priorities of pediatric services (such as feeling that the
pediatrician has not managed the patient correctly or has
transferred the patient either too early or too late).
& CONCLUSION
Historically, many children died with organ failure prior
to the introduction of transplantation. Solid organ trans-
plantation has revolutionized the lives of these patients, and
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there have been improvements in both patient and allograft
survival rates through advances in medical therapies and
surgical techniques. However, significant ongoing morbid-
ities are still associated with the patients’ underlying
chronic conditions and transplantation. The challenge for
the future is to individualize care, including tailoring
immunosuppressive therapies to minimize acute and
chronic allograft dysfunction and rejection and the treat-
ment of infectious, metabolic, cardiovascular and other
complications of transplantation.
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